Rallybio

Yahoo Finance • last month

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Rallybio Corporation (Nasdaq – RLYB), SunOpta Inc. (Nasdaq – STKL), Talkspace, Inc. (Nasdaq - TALK), Kennedy-Wilson Holdings, Inc. (Nasdaq - KW)

BALA CYNWYD, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ac... Full story

Yahoo Finance • last month

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in t... Full story

Yahoo Finance • 2 months ago

Rallybio to acquire Candid Therapeutics

US-based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction. Following completion, the combined entity will operate as Candid Therapeutics and list on Nasdaq under... Full story

Yahoo Finance • 6 months ago

After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers

(RTTNews) - Several biotechnology and pharmaceutical stocks showed notable price increases during Friday's after-hours trading session, with movement driven by upcoming data releases, recent earnings reports, and prior corporate updates.... Full story

Yahoo Finance • 7 months ago

After-Hours Movers: Biotech And Medtech Stocks Jump On Volume And News

(RTTNews) - A wave of after-hours activity swept through select biotech and medical device names Thursday, with several micro- and mid-cap stocks posting sharp gains following session-end catalysts, volume spikes, or pipeline updates. Belo... Full story

Yahoo Finance • 9 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Recursion Pharmaceuticals Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWS... Full story

Yahoo Finance • 10 months ago

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia, to joint venture partner Recursion... Full story

Yahoo Finance • 10 months ago

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interes... Full story

Yahoo Finance • 3 years ago

5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

SAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis i... Full story